Description
ADCC-Enhanced anti-TL1a is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Experimental Autoimmune Encephalomyelitis; Inflammatory Bowel Disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TL1a antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
tumor necrosis factor (ligand) superfamily, member 15
Background
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene.
Alternative Names
TNFSF15; tumor necrosis factor (ligand) superfamily, member 15; TL1; TL1A; VEGI; VEGI192A; tumor necrosis factor ligand superfamily member 15; TNF superfamily ligand TL1A; TNF ligand-related molecule 1; vascular endothelial cell growth inhibitor; vascular endothelial growth inhibitor-192A
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with TNFSF15 include Primary Biliary Cirrhosis and Diverticulitis.
Related Pathways
Its related pathways are Apoptosis Modulation and Signaling and TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions.
Function
Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.
Post-translational modifications
Glycosylation at Asn133 and Asn229
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The antibody which binds specifically to TL1a is used in several immune-mediated conditions, such as, experimental autoimmune encephalomyelitis (EAE; a model of multiple sclerosis), colitis, inflammatory bowel disease, asthma and arthritis. TLla has also been shown to promote formation of foam cells and atherosclerotic plaques.
Antibody Indication
Experimental Autoimmune Encephalomyelitis; Inflammatory Bowel Disease
